for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MannKind Corporation

MNKD.OQ

Latest Trade

1.32USD

Change

0.00(0.00%)

Volume

1,393,536

Today's Range

1.26

 - 

1.34

52 Week Range

0.94

 - 

2.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.32
Open
1.32
Volume
1,393,536
3M AVG Volume
47.61
Today's High
1.34
Today's Low
1.26
52 Week High
2.34
52 Week Low
0.94
Shares Out (MIL)
189.62
Market Cap (MIL)
250.29
Forward P/E
-4.16
Dividend (Yield %)
--

Next Event

MannKind Corp at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Mannkind Q2 Loss Per Share $0.07

Mannkind Repays Maturing Debt Obligation Buys Back Certain Warrants

MannKind's Afrezza Inhalation Powder Approved In Brazil

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MannKind Corporation

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry

Biotechnology & Drugs

Contact Info

30930 Russell Ranch Rd Ste 300

+1.818.6615000

http://www.mannkindcorp.com

Executive Leadership

Kent Kresa

Independent Chairman of the Board

Michael E. Castagna

Chief Executive Officer, Director

Steven B. Binder

Chief Financial Officer

David B. Thomson

Executive Vice President, General Counsel, Secretary

Rosabel Realica Alinaya

Senior Vice President, Treasurer

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

1.360

2017

-1.120

2018

-0.600

2019(E)

-0.318
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.73
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
-85.01

Latest News

BRIEF-Mannkind Q1 Loss Per Share $0.25

* Q1 REVENUE ROSE 15 PERCENT TO $3.4 MILLION Source text for Eikon: Further company coverage:

BRIEF-Cipla Partners With Mannkind For Marketing, Distribution Of Afrezza In India

* PARTNERS WITH MANNKIND FOR EXCLUSIVE MARKETING, DISTRIBUTION OF AFREZZA IN INDIA

BRIEF-Mannkind And Cipla Enter An Exclusive Marketing And Distribution Agreement For Afrezza® In India

* MANNKIND AND CIPLA ENTER AN EXCLUSIVE MARKETING AND DISTRIBUTION AGREEMENT FOR AFREZZA® IN INDIA

BRIEF-Mannkind Announces $28.0 Million Registered Direct Offering

* MANNKIND ANNOUNCES $28.0 MILLION REGISTERED DIRECT OFFERING

BRIEF-MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group

* MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION

BRIEF-Mannkind Corporation Q4 Loss Per Share $0.28

* ORATION REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES Source text for Eikon: Further company coverage:

BRIEF-Mannkind, On Jan 18, Co, Unit Entered Into Exchange, Sixth Amendment To Facility Agreement With Deerfield

* MANNKIND - ON JAN 18, CO AND UNIT ENTERED INTO AN EXCHANGE AND SIXTH AMENDMENT TO FACILITY AGREEMENT WITH DEERFIELD - SEC FILING

BRIEF-Mannkind Q3 loss per share $0.31

* Mannkind Corporation reports 2017 third quarter financial results

BRIEF-Mannkind restructures near-term debt obligations

* Mannkind Corp - extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock

BRIEF-Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

* Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)

BRIEF-Mannkind Corp resolved to voluntary delist from Tel Aviv Stock Exchange Ltd

* Mannkind corp - on august 4, board resolved to voluntary delist its common stock from tel aviv stock exchange ltd - sec filing

BRIEF-MannKind Corporation reports 2017 second quarter financial results

* Q2 revenue $2.2 million Source text for Eikon: Further company coverage:

BRIEF-MannKind and One Drop partner to launch the A-one clinical trial

* MannKind and One Drop partner to launch the A-one clinical trial

BRIEF-Steven Binder joins MannKind as Chief Financial Officer

* MannKind Corp - Steven Binder has joined company as its Chief Financial Officer Source text for Eikon: Further company coverage:

BRIEF-Mannkind files for offer and sale of up to 7.3 mln shares of common stock issuable upon exercise of Series A common stock purchase warrants

* Mannkind Corp files for offer and sale of up to 7.3 million shares of common stock issuable upon exercise of Series A common stock purchase warrants

BRIEF-Mannkind renegotiates near-term maturities with Deerfield

* Mannkind-Deerfield to amend terms of minimum liquidity covenant such that each month from October to December, company must maintain at least $10 million of cash & cash equivalents

BRIEF-Mannkind draws remaining funds under Mann Group loan arrangement

* Mannkind- delivered funding request notification to Mann Group pursuant to terms of Mann Group loan

BRIEF-Mannkind engages Locust Walk to explore strategic options for non-insulin technosphere-based pipeline candidates

* Mannkind engages Locust Walk to explore strategic options for Mannkind’s non-insulin technosphere-based pipeline candidates

BRIEF-Mannkind and Biomm enter into distribution agreement for Afrezza in Brazil​

* Mannkind and Biomm enter into distribution agreement for Afrezza in Brazil Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up